Skip to content

Citius Oncology, Inc.: 10-Q filed 2025-08-12

What Citius Oncology, Inc. reported in its quarterly report filed 2025-08-12 (fiscal Q3 2025): 29 published measures, 89 facts as tagged in accession 0001213900-25-074992.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-12
Fiscal period
fiscal Q3 2025
Accession
0001213900-25-074992 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Oncology, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-3091,709,079USD
At 2024-09-3084,368,878USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-3059,311,166USD
At 2024-09-3038,228,539USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-3032,397,913USD
At 2025-03-3135,642,632USD
At 2024-12-3141,289,612USD
At 2024-09-3046,140,339USD
At 2024-06-3017,030,861USD
At 2024-03-3119,846,711USD
At 2023-12-3122,725,257USD
At 2023-09-3025,535,660USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-06-30112USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-5,369,956USD91
2024-10-01 to 2025-06-30-19,764,713USD273
2025-01-01 to 2025-03-31-7,735,552USD90
2024-10-01 to 2024-12-31-6,659,205USD92
2024-04-01 to 2024-06-30-4,772,850USD91
2023-10-01 to 2024-06-30-14,335,799USD274
2024-01-01 to 2024-03-31-4,835,546USD91
2023-10-01 to 2023-12-31-4,727,403USD92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-59,043,300USD
At 2024-09-30-39,278,587USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-04-01 to 2025-06-3071,552,402shares91
2024-10-01 to 2025-06-3071,552,402shares273
2024-04-01 to 2024-06-3067,500,000shares91
2023-10-01 to 2024-06-3067,500,000shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-3071,552,402shares91
2024-10-01 to 2025-06-3071,552,402shares273
2024-04-01 to 2024-06-3067,500,000shares91
2023-10-01 to 2024-06-3067,500,000shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.08USD/shares91
2024-10-01 to 2025-06-30-0.28USD/shares273
2024-04-01 to 2024-06-30-0.07USD/shares91
2023-10-01 to 2024-06-30-0.21USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.08USD/shares91
2024-10-01 to 2025-06-30-0.28USD/shares273
2024-04-01 to 2024-06-30-0.07USD/shares91
2023-10-01 to 2024-06-30-0.21USD/shares274

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-04-01 to 2025-06-30264,240USD91
2024-10-01 to 2025-06-30792,720USD273
2024-04-01 to 2024-06-30144,000USD91
2023-10-01 to 2024-06-30432,000USD274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-04-01 to 2025-06-302,125,237USD91
2024-10-01 to 2025-06-306,022,287USD273
2024-04-01 to 2024-06-301,957,000USD91
2023-10-01 to 2024-06-305,831,000USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,944,961USD91
2024-10-01 to 2025-06-30-18,811,238USD273
2024-04-01 to 2024-06-30-4,628,850USD91
2023-10-01 to 2024-06-30-13,903,799USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-3018,309,079USD
At 2024-09-3010,968,878USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-3052,990,335USD
At 2024-09-3032,700,428USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-06-308,667,419USD
At 2024-09-303,711,622USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-304,944,961USD91
2024-10-01 to 2025-06-3018,811,238USD273
2024-04-01 to 2024-06-304,628,850USD91
2023-10-01 to 2024-06-3013,903,799USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-06-3017,208,967USD
At 2024-09-308,268,766USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-30938,277USD91
2024-10-01 to 2025-06-305,342,198USD273
2024-04-01 to 2024-06-301,131,439USD91
2023-10-01 to 2024-06-303,628,900USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3071,552,402shares
At 2024-09-3071,552,402shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-30112USD
At 2024-09-30112USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-3091,434,058USD
At 2024-09-3085,411,771USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-06-308,458,554USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2025-06-302,520,720USD
At 2024-09-301,728,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-5,105,716USD91
2024-10-01 to 2025-06-30-18,971,993USD273
2024-04-01 to 2024-06-30-4,628,850USD91
2023-10-01 to 2024-06-30-13,903,799USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-301,881,447USD91
2024-10-01 to 2025-06-307,446,753USD273
2024-04-01 to 2024-06-301,540,411USD91
2023-10-01 to 2024-06-304,443,899USD274

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-04-01 to 2025-06-30160,755USD91
2024-10-01 to 2025-06-30160,755USD273

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2024-10-01 to 2025-06-30792,720USD273
2023-10-01 to 2024-06-30432,000USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-10-01 to 2025-06-308,940,201USD273

Inspect the source

Entity
Citius Oncology, Inc. / CIK 0001851484
Captured
2026-09-21T17:32:34.031Z
SEC response SHA-256
1e8c39a029a9529c1971ba7b07551c1ef4dd6de443d807231887851f2cef037a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001851484.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))